
A Promising Cutting-Edge AI Skin Cancer Screening Device | |
The FDA has greenlit DermaSensor, marking the maiden voyage of an AI-powered medical device aimed at aiding healthcare providers in identifying prevalent skin cancer types. Unlike a broad screening tool, DermaSensor zooms in on lesions previously flagged as suspicious, offering a closer inspection to healthcare professionals. Solely available via prescription for healthcare provider use, it isn’t intended for public or home use. Armed with an AI algorithm, DermaSensor, a wireless handheld device, scrutinizes the appearance of suspicious skin lesions, providing insights into subsequent actions for providers. The device’s advent is expected to empower around 300,000 primary care providers in the U.S. to administer point-of-care diagnostic tests for common skin cancers, potentially expediting access to necessary care. The device fills a void in primary care, where evaluation of suspicious moles has traditionally relied on subjective judgment and clinical training. Michele Green, MD, a cosmetic dermatologist at Northwell Lenox Hill Hospital, likened DermaSensor to a flashlight for non-specialist healthcare providers, enabling them to refer patients to dermatologists when warranted. For more details please visit our website - https://www.medhealthinsight.com/new-soundboard-review-pricing-is-not-always-the-only-criteria-2-11-2-68/ ![]() | |
| Related Link: Click here to visit item owner's website (0 hit) | |
| Target State: New York Target City : New York City Last Update : Oct 25, 2025 6:50 AM Number of Views: 19 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
| Friendly reminder: Click here to read some tips. | |